 Ashley Frazer-Abel
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 14 | 2022 | 294 | 4.270 |
Why?
| | Complement Activation | 11 | 2022 | 350 | 1.210 |
Why?
| | Laboratories | 2 | 2021 | 97 | 0.930 |
Why?
| | Immunoassay | 2 | 2021 | 101 | 0.830 |
Why?
| | Clinical Laboratory Techniques | 2 | 2018 | 89 | 0.720 |
Why?
| | Laboratories, Hospital | 1 | 2018 | 13 | 0.670 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 95 | 0.630 |
Why?
| | RNA, Transfer | 2 | 2008 | 119 | 0.540 |
Why?
| | Angioedemas, Hereditary | 2 | 2014 | 7 | 0.540 |
Why?
| | Macular Degeneration | 3 | 2022 | 151 | 0.510 |
Why?
| | RNA | 3 | 2008 | 833 | 0.480 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 667 | 0.480 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 398 | 0.470 |
Why?
| | Complement Factor B | 4 | 2022 | 102 | 0.450 |
Why?
| | Anticodon | 2 | 2004 | 22 | 0.430 |
Why?
| | Angioedema | 1 | 2011 | 17 | 0.400 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2021 | 89 | 0.400 |
Why?
| | Nucleic Acid Conformation | 3 | 2008 | 670 | 0.400 |
Why?
| | Emergency Responders | 2 | 2021 | 34 | 0.390 |
Why?
| | T-Lymphocytes | 3 | 2009 | 1774 | 0.350 |
Why?
| | Immunologic Tests | 2 | 2021 | 16 | 0.350 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 160 | 0.350 |
Why?
| | Autoantibodies | 3 | 2021 | 1335 | 0.350 |
Why?
| | Cyclin-Dependent Kinase 4 | 2 | 2006 | 32 | 0.340 |
Why?
| | Specimen Handling | 2 | 2022 | 165 | 0.340 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2019 | 128 | 0.330 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 989 | 0.310 |
Why?
| | Humans | 44 | 2023 | 118972 | 0.300 |
Why?
| | Smoking | 3 | 2019 | 1487 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2021 | 439 | 0.290 |
Why?
| | Tars | 1 | 2006 | 4 | 0.290 |
Why?
| | Complement Factor H | 2 | 2019 | 61 | 0.280 |
Why?
| | Nicotine | 2 | 2009 | 276 | 0.280 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 37 | 0.280 |
Why?
| | Complement C3a | 3 | 2019 | 33 | 0.260 |
Why?
| | Cell Cycle | 2 | 2006 | 550 | 0.260 |
Why?
| | RNA, Transfer, Ser | 2 | 2008 | 4 | 0.260 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2023 | 20 | 0.230 |
Why?
| | Quality Control | 2 | 2021 | 159 | 0.230 |
Why?
| | Vitreous Body | 2 | 2022 | 104 | 0.230 |
Why?
| | Disease Susceptibility | 4 | 2020 | 331 | 0.230 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 25 | 0.230 |
Why?
| | Trichloroethylene | 1 | 2022 | 7 | 0.220 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 112 | 0.210 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 15 | 0.210 |
Why?
| | Protein Aggregates | 2 | 2019 | 70 | 0.210 |
Why?
| | Nuclear Proteins | 2 | 2004 | 597 | 0.210 |
Why?
| | Complement Inactivator Proteins | 1 | 2021 | 39 | 0.200 |
Why?
| | Extracellular Traps | 1 | 2021 | 40 | 0.200 |
Why?
| | Cross Reactions | 1 | 2021 | 116 | 0.200 |
Why?
| | Europe | 2 | 2020 | 356 | 0.200 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.190 |
Why?
| | Retinal Drusen | 1 | 2021 | 25 | 0.190 |
Why?
| | Immunologic Factors | 2 | 2022 | 225 | 0.190 |
Why?
| | Magnesium | 3 | 2008 | 150 | 0.180 |
Why?
| | Sputum | 1 | 2021 | 290 | 0.180 |
Why?
| | Polyvinyl Chloride | 1 | 2019 | 5 | 0.180 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 9 | 0.180 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 35 | 0.170 |
Why?
| | Biological Products | 1 | 2022 | 170 | 0.170 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 330 | 0.170 |
Why?
| | Occupational Exposure | 1 | 2022 | 277 | 0.170 |
Why?
| | Complement C3 | 2 | 2019 | 192 | 0.170 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 32 | 0.170 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.170 |
Why?
| | Geographic Atrophy | 1 | 2019 | 49 | 0.170 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 156 | 0.170 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 76 | 0.170 |
Why?
| | Mass Spectrometry | 1 | 2021 | 681 | 0.160 |
Why?
| | DNA-Binding Proteins | 2 | 2004 | 1346 | 0.150 |
Why?
| | Transcription Factors | 3 | 2004 | 1570 | 0.150 |
Why?
| | Complement Inactivating Agents | 1 | 2017 | 43 | 0.150 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 49 | 0.150 |
Why?
| | Complement C3 Nephritic Factor | 1 | 2016 | 1 | 0.140 |
Why?
| | Inflammation | 4 | 2021 | 2566 | 0.140 |
Why?
| | Complement C5 | 1 | 2016 | 75 | 0.140 |
Why?
| | Riboflavin | 1 | 2016 | 7 | 0.140 |
Why?
| | Virus Inactivation | 1 | 2016 | 8 | 0.140 |
Why?
| | Critical Illness | 1 | 2021 | 662 | 0.140 |
Why?
| | Ebolavirus | 1 | 2016 | 34 | 0.140 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2016 | 34 | 0.140 |
Why?
| | Blood | 1 | 2016 | 100 | 0.130 |
Why?
| | RNA, Fungal | 3 | 2008 | 66 | 0.130 |
Why?
| | Nanoparticles | 1 | 2019 | 325 | 0.130 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2015 | 39 | 0.130 |
Why?
| | Animals | 10 | 2022 | 33381 | 0.130 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2014 | 8 | 0.130 |
Why?
| | RNA, Transfer, Phe | 2 | 2008 | 10 | 0.130 |
Why?
| | Oligoribonucleotides | 1 | 2014 | 52 | 0.130 |
Why?
| | Disinfection | 1 | 2016 | 108 | 0.130 |
Why?
| | Autoimmunity | 1 | 2020 | 831 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 709 | 0.120 |
Why?
| | Oligonucleotides, Antisense | 1 | 2014 | 100 | 0.120 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 332 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 942 | 0.120 |
Why?
| | Antibodies, Viral | 3 | 2022 | 542 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 381 | 0.110 |
Why?
| | Comprehension | 1 | 2014 | 163 | 0.110 |
Why?
| | Pyrrolidinones | 1 | 2012 | 25 | 0.110 |
Why?
| | Base Sequence | 2 | 2008 | 2159 | 0.110 |
Why?
| | Birefringence | 2 | 2004 | 7 | 0.110 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2011 | 6 | 0.100 |
Why?
| | Complement C4 | 1 | 2011 | 26 | 0.100 |
Why?
| | Cattle | 2 | 2008 | 978 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 146 | 0.100 |
Why?
| | Female | 15 | 2022 | 61564 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2020 | 3171 | 0.100 |
Why?
| | Male | 14 | 2022 | 57801 | 0.090 |
Why?
| | Mutation | 2 | 2020 | 3457 | 0.090 |
Why?
| | Oligonucleotides | 2 | 2014 | 140 | 0.090 |
Why?
| | Complement C5a | 2 | 2019 | 60 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2871 | 0.090 |
Why?
| | Inflammation Mediators | 1 | 2012 | 502 | 0.090 |
Why?
| | Drug Packaging | 2 | 2019 | 44 | 0.090 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 110 | 0.080 |
Why?
| | Particle Size | 2 | 2019 | 345 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2008 | 171 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3003 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 334 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 2 | 2004 | 618 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2022 | 788 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2006 | 4077 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1384 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3360 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 1067 | 0.070 |
Why?
| | Middle Aged | 8 | 2021 | 27617 | 0.070 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.070 |
Why?
| | Enzyme Induction | 1 | 2006 | 94 | 0.070 |
Why?
| | Cell Survival | 1 | 2009 | 1047 | 0.070 |
Why?
| | G1 Phase | 1 | 2006 | 68 | 0.070 |
Why?
| | Temperature | 1 | 2008 | 622 | 0.070 |
Why?
| | Phenols | 1 | 2006 | 85 | 0.070 |
Why?
| | Macaca fascicularis | 2 | 2016 | 53 | 0.070 |
Why?
| | Aged | 6 | 2021 | 19657 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 827 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3588 | 0.060 |
Why?
| | Hemangiosarcoma | 1 | 2004 | 19 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 82 | 0.060 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2004 | 84 | 0.060 |
Why?
| | Dog Diseases | 1 | 2004 | 44 | 0.060 |
Why?
| | Plasmids | 1 | 2004 | 355 | 0.060 |
Why?
| | Adult | 7 | 2021 | 31512 | 0.060 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2004 | 111 | 0.060 |
Why?
| | Rare Diseases | 1 | 2023 | 113 | 0.060 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2022 | 55 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 287 | 0.050 |
Why?
| | United States | 1 | 2018 | 12555 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 100 | 0.050 |
Why?
| | Cytokines | 2 | 2012 | 1900 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 107 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 161 | 0.050 |
Why?
| | Colorado | 2 | 2021 | 4196 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 282 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 130 | 0.050 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 94 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2022 | 253 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 527 | 0.050 |
Why?
| | Vitrectomy | 1 | 2020 | 58 | 0.050 |
Why?
| | Apoptosis | 1 | 2009 | 2484 | 0.050 |
Why?
| | Complement C4a | 1 | 2019 | 7 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 13 | 0.040 |
Why?
| | Syringes | 1 | 2019 | 37 | 0.040 |
Why?
| | Freezing | 1 | 2019 | 87 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 90 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 54 | 0.040 |
Why?
| | South Carolina | 1 | 2019 | 38 | 0.040 |
Why?
| | Cations, Divalent | 1 | 1999 | 52 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 135 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 103 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2490 | 0.040 |
Why?
| | Drug Stability | 1 | 2019 | 153 | 0.040 |
Why?
| | Rheology | 1 | 2019 | 87 | 0.040 |
Why?
| | Yeasts | 1 | 1999 | 52 | 0.040 |
Why?
| | Protein Stability | 1 | 2019 | 164 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2004 | 2657 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2275 | 0.040 |
Why?
| | Body Mass Index | 2 | 2019 | 2092 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 126 | 0.040 |
Why?
| | Calcium | 1 | 2004 | 1169 | 0.040 |
Why?
| | HIV Infections | 1 | 2012 | 2459 | 0.040 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 46 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 397 | 0.040 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 19 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2019 | 443 | 0.040 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 18 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6561 | 0.040 |
Why?
| | Risk Factors | 2 | 2021 | 9000 | 0.040 |
Why?
| | Prolactin | 1 | 1997 | 96 | 0.040 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 91 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 465 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 389 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 635 | 0.040 |
Why?
| | Epitopes | 1 | 2019 | 443 | 0.040 |
Why?
| | Motivation | 1 | 2021 | 506 | 0.040 |
Why?
| | Adolescent | 4 | 2016 | 18480 | 0.040 |
Why?
| | Mice | 2 | 2022 | 15520 | 0.040 |
Why?
| | Complement Pathway, Alternative | 1 | 2017 | 117 | 0.040 |
Why?
| | Odds Ratio | 1 | 2019 | 996 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 571 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 175 | 0.040 |
Why?
| | Vero Cells | 1 | 2016 | 69 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 703 | 0.030 |
Why?
| | Complement C5b | 1 | 2015 | 4 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2513 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 227 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2020 | 699 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 356 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1997 | 282 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2014 | 2071 | 0.030 |
Why?
| | Child | 3 | 2021 | 19129 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1353 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 325 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 278 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 1901 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1489 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1997 | 348 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2162 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1997 | 1158 | 0.030 |
Why?
| | CD4-CD8 Ratio | 1 | 2012 | 19 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 12 | 0.030 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 20 | 0.030 |
Why?
| | Raltegravir Potassium | 1 | 2012 | 16 | 0.030 |
Why?
| | Funnel Chest | 1 | 2012 | 23 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2012 | 48 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1515 | 0.030 |
Why?
| | Adipokines | 1 | 2012 | 46 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1440 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4552 | 0.030 |
Why?
| | Age Factors | 1 | 2019 | 2995 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4596 | 0.030 |
Why?
| | Signal Transduction | 2 | 2009 | 4709 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 260 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 419 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2012 | 313 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1687 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 183 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 2009 | 4 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1945 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6471 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2009 | 134 | 0.020 |
Why?
| | Young Adult | 2 | 2014 | 10793 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6412 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1541 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 606 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1997 | 2445 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1419 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 702 | 0.020 |
Why?
| | Receptors, Nicotinic | 1 | 2009 | 295 | 0.020 |
Why?
| | HIV-1 | 1 | 2012 | 776 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 984 | 0.020 |
Why?
| | Ploidies | 1 | 2004 | 18 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 154 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 371 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 443 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 776 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12978 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 460 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 9491 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 896 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1997 | 23 | 0.010 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 1997 | 18 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 46 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 51 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 907 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 175 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1997 | 49 | 0.010 |
Why?
| | Coenzymes | 1 | 1997 | 20 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 2851 | 0.010 |
Why?
| | Catalysis | 1 | 1997 | 295 | 0.010 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 1997 | 67 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 237 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1715 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1997 | 130 | 0.010 |
Why?
| | Mediator Complex | 1 | 1997 | 52 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 874 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 888 | 0.010 |
Why?
| | Binding Sites | 1 | 1997 | 1224 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 407 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 468 | 0.010 |
Why?
| | Protein Binding | 1 | 1997 | 1975 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5392 | 0.010 |
Why?
|
|
Frazer-Abel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|